Patents by Inventor David Edward Tupper
David Edward Tupper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9296710Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder.Type: GrantFiled: June 7, 2012Date of Patent: March 29, 2016Assignee: Eli Lilly and CompanyInventors: Teresa Tse Ki Man, James Allen Monn, Carlos Montero Salgado, Lourdes Prieto, David Edward Tupper, Lesley Walton
-
Publication number: 20140113944Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder.Type: ApplicationFiled: June 7, 2012Publication date: April 24, 2014Applicant: ELI LILLY AND COMPANYInventors: Teresa Tse Ki Man, James Allen Monn, Carlos Montero Salgado, Lourdes Prieto, David Edward Tupper, Lesley Walton
-
Patent number: 8168659Abstract: Compounds and pharmaceutical compositions comprising compounds of the Formula as CB1 receptor inverse agonists useful for reducing body weight in mammals, treating cognitive impairment associated with schizophrenia, and mitigating treatment emergent weight gain observed during treatment with antipsychotics.Type: GrantFiled: October 22, 2007Date of Patent: May 1, 2012Assignee: Eli Lilly and CompanyInventors: David Scott Coffey, Jingdan Hu, Stacy Jo Keding, Joseph Herman Krushinski, Jr., John Mehnert Schaus, David Edward Tupper
-
Publication number: 20090275618Abstract: Compounds and pharmaceutical compositions of Formula (I) by blockade of the CB1 receptors via an inverse agonism mechanism which are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and have increased bioavailability.Type: ApplicationFiled: October 22, 2007Publication date: November 5, 2009Inventors: David Scott Coffey, Jingdan Hu, Stacy Jo Keding, Joseph Herman Krushinski, JR., John Mehnert Schaus, David Edward Tupper
-
Patent number: 7384934Abstract: Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C1-4) alkylene or hydroxy substituted (C1-4) alkylene; X is oxygen or sulfur; R1 is hydrogen, (C1-6) fluroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, or —CN; R2 is H, halogen, (C1-6) fluoroalkyl, (C1-6) cycloalkyl, OR4, SR4, NO2, CN, COR4, C(O)OR4, CONR5R6, NR5R6, SO2NR5R6, NR5COR4, NR5SO2R4, optionally substituted aromatic, or (C1-6) alkyl, wherein (C1-6) alkyl is unsubstituted or substituted with a hydroxy group; R3 is hydrogen (C1-6) fluoroalkyl, (C2-6) alkenyl, Ar, (C1-4)alkyl-Ar, or (C1-4) alkyl wherein (C1-4) alkyly is unsubstituted or substituted with a phenyl; R4 is hydrogen, (C1-6) alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionallyType: GrantFiled: July 28, 2003Date of Patent: June 10, 2008Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Zhaogen Chen, Yvan LeHuerou, Fionna Mitchell Martin, Marta Maria Pineiro-Nunez, Vincent Patrick Rocco, Kevin Michael Ruley, John Mehnert Schaus, Patrick Gianpietro Spinazze, David Edward Tupper
-
Patent number: 7214673Abstract: Described herein are antipyschotic compounds of formula (I) wherein, A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; Alk is (C1-4) alkylene optionally substituted with OH, methoxy, ethoxy, or F; Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic, or bicyclic heteroaromatic; R1 is hydrogen or (C1-4) alkyl optionally substituted with OH, OR3, or OCH2CH2OH, wherein R3 is (C1-2) alkyl; R2 is H, (C1-6) alkyl, halogen, fluorinated (C1-6) alkyl, OR4, SR4, NO2, CN, COR4, CONR5R6, SO2NR5R6, NR5R6, NR5COR4, NR5SO2R4, or optionally substituted phenyl, wherein R4 is hydrogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, or optionally substituted phenyl, R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted phenyl; Z is one or two substituents independently selected from hydrogen, halogen, (C1-6) alkyl, fluorinated (C1-6) alkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, SO2NR8R9, NR8SO2RType: GrantFiled: March 17, 2003Date of Patent: May 8, 2007Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Zhaogen Chen, Joseph Herman Krushinski, Jr., Yvan Le Huerou, Marta Maria Pineiro-Nunez, Kevin Michael Ruley, John Mehnert Schaus, Dennis Charles Thompson, David Edward Tupper, Ying Chen, Margaret Mary Faul, Vincent Patrick Rocco
-
Publication number: 20040030131Abstract: A compound of the formula in which R1 and R2 are each hydrogen or C1-4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholino group, said group being optionally substituted with 1 to 3 substituents selected from C1-4 alkyl, hydroxymethyl, C1-4 alkoxymethyl and amido, R3 is a naphthyl, indolyl, benzothienyl, benzofuranyl, benzothiazolyl, quinolinyl or isoquinolinyl group, said group being optionally substituted, and n is 1 or 2; and m is 0 or 1, provided that when m is 1 then n is 1; or a salt or ester thereof.Type: ApplicationFiled: September 3, 2003Publication date: February 12, 2004Inventors: Martine Keenan, Vincent Patrick Rocco, Kumiko Takeuchi, David Edward Tupper, Vincent Vivien
-
Patent number: 6384281Abstract: A pharmaceutical compound of formula (I) in which R1 and R2 are each hydrogen or C1-4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholino group, said group being optionally substituted with 1 to 3 C1-4alkyl substituents, R3 is a naphythyl, indolyl, benzothienyl, benzofuranyl, benzothiazolyl, quinolinyl or isoquinolinyl group, said group being optionally substituted, and n is 1 or 2; or a salt or ester thereof.Type: GrantFiled: October 3, 2001Date of Patent: May 7, 2002Assignee: Eli Lilly and CompanyInventors: Martine Keenan, Sandra Ginette Milutinovic, David Edward Tupper
-
Patent number: 6169084Abstract: The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.Type: GrantFiled: September 30, 1998Date of Patent: January 2, 2001Assignee: Eli Lilly and CompanyInventors: Charles Arthur Bunnell, Thomas Harry Ferguson, Barry Arnold Hendriksen, Manuel Vicente Sanchez-Felix, David Edward Tupper
-
Patent number: 6034078Abstract: Pharmaceutical compounds of the formula ##STR1## in which R.sup.1 is hydrogen or halo, and R.sup.2 is C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-6 cycloalkyl optionally substituted by 1 to 3 C.sub.1-4 alkyl groups, C.sub.3-6 cycloalkyl-C.sub.1-4 alkyl in which the cycloalkyl group is optionally substituted by 1 to 3 C.sub.1-4 alkyl groups, or optionally substituted phenyl-C.sub.1-4 alkyl; or a salt thereof. Such compounds are useful for treating a disorder of the central nervous system which is associated with the modulation of a 5-HT.sub.3 receptor.Type: GrantFiled: July 1, 1997Date of Patent: March 7, 2000Assignees: Eli Lilly and Company Limited, Eli Lilly and CompanyInventors: John Fairhurst, Terrence Michael Hotten, David Edward Tupper, David Taiwai Wong
-
Patent number: 6008216Abstract: 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system.Type: GrantFiled: July 24, 1998Date of Patent: December 28, 1999Assignee: Eli Lilly And Company and LimitedInventors: Jiban Kumar Chakrabarti, Terrence Michael Hotten, David Edward Tupper
-
Patent number: 5817655Abstract: 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno -?2,3-b!?1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system.Type: GrantFiled: November 13, 1996Date of Patent: October 6, 1998Assignees: Eli Lilly and Company, Eli Lilly and Company LimitedInventors: Jiban Kumar Chakrabarti, Terrence Micharl Hotten, David Edward Tupper
-
Patent number: 5817656Abstract: 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-?2,3-b!?1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of mental disorders.Type: GrantFiled: November 13, 1996Date of Patent: October 6, 1998Assignees: Eli Lilly and Company, Eli Lilly and Company LimitedInventors: Charles M. Beasley, Jr., Jiban Kumar Chakrabarti, Terrence Michael Hotten, David Edward Tupper
-
Patent number: 5817657Abstract: 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-?2,3-b!?1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders relating to the use of psychoactive substances.Type: GrantFiled: November 13, 1996Date of Patent: October 6, 1998Assignees: Eli Lilly and Company, Eli Lilly and Company LimitedInventors: Charles M. Beasley, Jr., Jiban Kumar Chakrabarti, Terrence Michael Hotten, David Edward Tupper
-
Patent number: 5703232Abstract: The invention provides lower alcohol solvates of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno?2,3-b!?1,5!benzodiazepine (olanzapine) and a process for making such lower alcohol solvates of olanzapine. The invention provides a method for using such solvates of olanzapine to prepare substantially pure anhydrous Form I 2-methyl-thieno-benzodiazepine.Type: GrantFiled: January 16, 1996Date of Patent: December 30, 1997Assignee: Eli Lilly and CompanyInventors: Charles A. Bunnell, Terrence Michael Hotten, Samuel D. Larsen, David Edward Tupper
-
Patent number: 4115568Abstract: Thieno[1,5]benzodiazepines having useful CNS activity containing the novel tricyclic ring system: ##STR1## the 10-position being substituted by an amino, preferably a piperazino, group.Type: GrantFiled: April 13, 1977Date of Patent: September 19, 1978Assignee: Lilly Industries LimitedInventors: Jiban Kumar Chakrabarti, David Edward Tupper
-
Patent number: 4115574Abstract: Thieno[1,5]benzodiazepines having useful CNS activity containing the novel tricyclic ring system: ##STR1## the 10-position being substituted by an amino, preferably a piperazino, group.Type: GrantFiled: June 1, 1977Date of Patent: September 19, 1978Assignee: Lilly Industries LimitedInventors: Jiban Kumar Chakrabarti, David Edward Tupper
-
Patent number: 4061774Abstract: Novel 2-substituted-1-methylamino adamantanes of formula: ##STR1## where X is hydroxyl or halogeno, and R.sup.1, R.sup.2 and R.sup.3 are hydrogen or C.sub.1-4 alkyl or R.sup.2 and R.sup.3 together with the nitrogen form a heterocyclic ring, having anti-Parkinsonian activity, pharmaceutical formulations containing the active adamantanes and novel 4-protoadamantane spiro oxirane and 1,2-difunctionalized intermediates useful in the preparation of the final products of the invention.Type: GrantFiled: April 9, 1975Date of Patent: December 6, 1977Assignee: Lilly Industries, LimitedInventors: Jiban Kumar Chakrabarti, Terrence Michael Hotten, David Edward Tupper
-
Patent number: RE40033Abstract: 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system.Type: GrantFiled: December 18, 2001Date of Patent: January 22, 2008Assignee: Eli Lilly and CompanyInventors: Reba Chakrabarti, Terrence Michael Hotten, David Edward Tupper, Jiban Kumar Chakrabarti